SAF

Integrated Continuous Glucose Monitor For Non-Intensive Glucose Monitoring, Over-The-Counter

Product code
SAF
Device name
Integrated Continuous Glucose Monitor For Non-Intensive Glucose Monitoring, Over-The-Counter
Device class
Class 2
21 CFR
21 CFR 862.1355
Medical specialty
Clinical Chemistry
Marketing pathway
510(K)
510(k) clearances (last 3 years)
4
Summaries archived here
2 (direct download)
510(k) clearances (all years, FDA)
4 (all years; only the last 3 years are listed here)

FDA classification definition

An integrated continuous glucose monitoring system (iCGM) for non-intensive glucose monitoring is intended to automatically measure glucose in bodily fluids continuously or frequently for a specified period of time to detect euglycemic and dysglycemic glucose levels in persons who are not on insulin and do not have a significant risk of problematic hypoglycemia. iCGM systems for non-intensive glucose monitoring are designed to reliably and securely transmit glucose measurement data to digitally connected devices, excluding devices intended to control the delivery of insulin, and are intended to be used alone or in conjunction with these digitally connected medical devices. Device output should not be used to make treatment decisions without consulting with a qualified healthcare professional.

Definition text from the FDA device classification database (U.S. federal government work, public domain).

510(k) clearances, last 3 years (4)

Last three years. Most recent: 2026-05-21.

NumberDecision dateApplicantDevice nameSummary
K2613592026-05-21Dexcom, Inc.Stelo Glucose Biosensor SystemPDF
K2501062025-03-21Signos, Inc.Signos Glucose Monitoring SystemFDA
K2336552024-05-29AbbottLingo Glucose SystemFDA
K2340702024-03-05Dexcom, Inc.Stelo Glucose Biosensor SystemPDF

2 summaries are archived here for direct download.

Official FDA classification page: SAF
Classification and pathway per current FDA publications. Data from openFDA (CC0).